Elizabeth A. Cromwell

Elizabeth A. Cromwell

Auto-generated profile, based on publicly available information

Elizabeth A. Cromwell

Cystic Fibrosis Foundation, Bethesda, MD, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2017 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
ECElizabeth A Cromwell
Elizabeth A Cromwell
SSSteven T Stoddard
Steven T Stoddard
CBChristopher M. Barker
Christopher M. Barker
ARAnnelies Van Rie
Annelies Van Rie
WMWilliam B Messer
William B Messer
TSThomas W Scott
Thomas W Scott
Routine entomological monitoring data are used to quantify the abundance of Ae. aegypti. The public health utility of these indicators is based on the assumption that greater mosquito abundance increases the risk of human DENV transmission, and therefore reducing exposure to the vector decreases incidence of infection. Entomological survey data from two longitudinal cohort studies in Iquitos, Peru, linked with 8,153 paired serological samples taken approximately six months apart were analyzed. Indicators of Ae. aegypti density were calculated from cross-sectional and longitudinal entomological data collected over a 12-month period for larval, pupal and adult Ae. aegypti. Log binomial models were used to estimate risk ratios (RR) to measure the association between Ae. aegypti abundance and the six-month risk of DENV seroconversion. RRs estimated using cross-sectional entomological data were compared to RRs estimated using longitudinal data. Higher cross-sectional Ae. aegypti densities were not associated with an increased risk of DENV seroconversion. Use of longitudinal entomological data resulted in RRs ranging from 1.01 (95% CI: 1.01, 1.02) to 1.30 (95% CI: 1.17, 1.46) for adult stage density estimates and RRs ranging from 1.21 (95% CI: 1.07, 1.37) to 1.75 (95% CI: 1.23, 2.5) for categorical immature indices. Ae. aegypti densities calculated from longitudinal entomological data were associated with DENV seroconversion, whereas those measured cross-sectionally were not. Ae. aegypti indicators calculated from cross-sectional surveillance, as is common practice, have limited public health utility in detecting areas or populations at high risk of DENV infection. In this study, we compared measures of entomological risk collected through routine household entomological monitoring by estimating an association with human DENV infection. Longitudinal entomological and human serology data from Iquitos, Peru, were used to test associations between Ae. aegypti indices and the 6-month risk of DENV seroconversion. Our analysis found no association between cross-sectional measures of Ae. aegypti abundance and the risk of DENV seroconversion. Longitudinal measures of Ae. aegypti were better proxies for DENV risk, primarily among adult stage mosquito indicators. DENV transmission is complex and time-varying; the relationship between vector density and risk is not static nor adequately characterized through periodic entomological surveillance. While entomological monitoring will continue to serve a role in the evaluation of vector control interventions (e.g., comparing pre- and post-intervention abundance), our analysis challenges the validity of most Ae. aegypti indicators as adequate proxies for true DENV exposure risk.

4 July 2017 in Malaria Journal
Verified
Journal Article
Open access
PDF file
ADAmare Deribew
Amare Deribew
TDTariku Dejene
Tariku Dejene
BKBiruck Kebede
Biruck Kebede
Gizachew TessemaGizachew Tessema
Gizachew Tessema
YMYohannes Adama Melaku
Yohannes Adama Melaku
JSJeffrey D. Stanaway
Jeffrey D. Stanaway
In Ethiopia there is no complete registration system to measure disease burden and risk factors accurately. In this study, the 2015 global burden of diseases, injuries and risk factors (GBD) data were used to analyse the incidence, prevalence and mortality rates of malaria in Ethiopia over the last 25 years. GBD 2015 used verbal autopsy surveys, reports, and published scientific articles to estimate the burden of malaria in Ethiopia. Age and gender-specific causes of death for malaria were estimated using cause of death ensemble modelling. The number of new cases of malaria declined from 2.8 million [95% uncertainty interval (UI) 1.4–4.5 million] in 1990 to 621,345 (95% UI 462,230–797,442) in 2015. Malaria caused an estimated 30,323 deaths (95% UI 11,533.3–61,215.3) in 1990 and 1561 deaths (95% UI 752.8–2660.5) in 2015, a 94.8% reduction over the 25 years. Age-standardized mortality rate of malaria has declined by 96.5% between 1990 and 2015 with an annual rate of change of 13.4%. Age-standardized malaria incidence rate among all ages and gender declined by 88.7% between 1990 and 2015. The number of disability-adjusted life years lost (DALY) due to malaria decreased from 2.2 million (95% UI 0.76–4.7 million) in 1990 to 0.18 million (95% UI 0.12–0.26 million) in 2015, with a total reduction 91.7%. Similarly, age-standardized DALY rate declined by 94.8% during the same period. Ethiopia has achieved a 50% reduction target of malaria of the millennium development goals. The country should strengthen its malaria control and treatment strategies to achieve the sustainable development goals.

13 March 2023 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
ECElizabeth A. Cromwell
Elizabeth A. Cromwell
JOJoshua S. Ostrenga
Joshua S. Ostrenga
JTJonathan V. Todd
Jonathan V. Todd
AEAlexander Elbert
Alexander Elbert
ABA. Whitney Brown
A. Whitney Brown
BMBruce C. Marshall
Bruce C. Marshall
The Cystic Fibrosis Foundation Patient Registry (CFFPR) collects data on individuals with cystic fibrosis (CF) in the United States (US). In 2012, the US CF population was estimated at 33,292 to 34,327 individuals, with 81-84% CFFPR participation. In this study, we update these estimates via simulation to account for uncertainty in CF incidence by race or Hispanic ethnicity, initiation of CF newborn screening (NBS) programs by state, and updated cumulative survival for CF births 1968-2020. We defined registry participation as the proportion of individuals alive as of 2020 with any prior CFFPR participation as well as the proportion with contributing data in 2019 or 2020; we summarize CFFPR participation for those born prior to 1968. We estimated the 2020 prevalent CF population between 1968-2020 to be 38,804 (95% Uncertainty Interval (UI): 38,532 to 39,065) individuals, with 77% of the prevalent CF population contributing recent data. CFFPR participation differs by age (54% of those born in 1968) and exceeds >90% of the population born in 2009 or later. We demonstrate that the CFFPR remains a valid data source generalizable to the CF population. High participation among younger individuals may reflect the success of newborn screening programs and early referral to CF care. If engagement can be sustained, the percentage of individuals participating in the CFFPR will grow over time and there is an opportunity to identify factors associated with loss to follow up among older individuals to optimize the quality of the CFFPR data.

9 November 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
ASAnne L. Stephenson
Anne L. Stephenson
SSSana Swaleh
Sana Swaleh
JSJenna Sykes
Jenna Sykes
SSSanja Stanojevic
Sanja Stanojevic
XMXiayi Ma
Xiayi Ma
CGChristopher H. Goss
Christopher H. Goss

28 July 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
ECElizabeth A. Cromwell
Elizabeth A. Cromwell
JOJoshua C. P. Osborne
Joshua C. P. Osborne
TUThomas Raymond Unnasch
Thomas Raymond Unnasch
MBMaria-Gloria Basanez
Maria-Gloria Basanez
KGKATHERINE GASS
KATHERINE GASS
DPDavid M. Pigott
David M. Pigott
Recent evidence suggests that, in some foci, elimination of onchocerciasis from Africa may be feasible with mass drug administration (MDA) of ivermectin. To achieve continental elimination of transmission, mapping surveys will need to be conducted across all implementation units (IUs) for which endemicity status is currently unknown. Using boosted regression tree models with optimised hyperparameter selection, we estimated environmental suitability for onchocerciasis at the 5 × 5-km resolution across Africa. In order to classify IUs that include locations that are environmentally suitable, we used receiver operating characteristic (ROC) analysis to identify an optimal threshold for suitability concordant with locations where onchocerciasis has been previously detected. This threshold value was then used to classify IUs (more suitable or less suitable) based on the location within the IU with the largest mean prediction. Mean estimates of environmental suitability suggest large areas across West and Central Africa, as well as focal areas of East Africa, are suitable for onchocerciasis transmission, consistent with the presence of current control and elimination of transmission efforts. The ROC analysis identified a mean environmental suitability index of 0·71 as a threshold to classify based on the location with the largest mean prediction within the IU. Of the IUs considered for mapping surveys, 50·2% exceed this threshold for suitability in at least one 5 × 5-km location. The formidable scale of data collection required to map onchocerciasis endemicity across the African continent presents an opportunity to use spatial data to identify areas likely to be suitable for onchocerciasis transmission. National onchocerciasis elimination programmes may wish to consider prioritising these IUs for mapping surveys as human resources, laboratory capacity, and programmatic schedules may constrain survey implementation, and possibly delaying MDA initiation in areas that would ultimately qualify.

9 February 2017 in AIDS Care
Verified
Journal Article
Closed access
AWAustin Wesevich
Austin Wesevich
TMTiwonge Mtande
Tiwonge Mtande
FSFriday Saidi
Friday Saidi
ECElizabeth Cromwell
Elizabeth Cromwell
HTHannock Tweya
Hannock Tweya
NRNora E. Rosenberg
Nora E. Rosenberg
Malawi’s Option B+ program provides all HIV-infected pregnant women free lifelong antiretroviral therapy (ART), but challenges remain regarding retention and ART adherence, potentially due to male partner barriers. We explored relationships between male partner involvement and Option B+ retention and adherence. In 2014, a randomized controlled trial in Malawi compared male recruitment strategies for couple HIV testing and counseling (cHTC) at an antenatal clinic. This secondary analysis was conducted among the entire cohort (N = 200) of women, irrespective of randomization status. We assessed whether cHTC attendance, early disclosure of HIV-positive status, and partner ART reminders were associated with retention and adherence at one month after starting treatment. Retention was defined as attending HIV clinic follow-up within one day of running out of pills. Adherence was defined as taking ≥95% of ARTs by pill count. We used binomial regression to calculate adjusted risk ratios (aRR) and 95% confidence intervals (CI). Median female age was 26 years. Most women (79%) were retained; of these, 68% were adherent. Receiving cHTC was associated with improved retention (aRR 1.33, 95% CI 1.12, 1.59). Receiving male partner ART reminders was weakly associated with retention (aRR 1.16, 95% CI 0.96, 1.39). Disclosure within one day was not associated with retention (aRR 1.08, 95% CI: 0.91, 1.28). Among those who were retained, these three behaviors were not associated with improved 95% adherence. CHTC could play an important role in improving Option B+ retention. Increasing cHTC participation and enhancing adherence-related messages within cHTC are important.